<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04232397</url>
  </required_header>
  <id_info>
    <org_study_id>SHSYXY-Anlo-cGVHD-2019001</org_study_id>
    <nct_id>NCT04232397</nct_id>
  </id_info>
  <brief_title>Anlotinib Treatment in Steroid Depenent/Refractory cGVHD</brief_title>
  <official_title>A Phase 2 Study of Anlotinib in Subjects With Steroid Depenent/Refractory Chronic Graft Versus Host Disease(cGVHD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center, single arm, prospective, phase II clinical study. The main purpose&#xD;
      of this study is to evaluate the efficacy and safety of anlotinib in the treatment of steroid&#xD;
      dependent/refractory chronic graft-versus-host disease (cGVHD) after allogeneic peripheral&#xD;
      blood stem cell transplantation (allo HSCT).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Anlotinib 8mg qd po for 6months if no progression in 4weeks or reach PR in 3months&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    the efficency is not good enough to enroll more patients&#xD;
  </why_stopped>
  <start_date type="Actual">April 10, 2020</start_date>
  <completion_date type="Actual">March 1, 2021</completion_date>
  <primary_completion_date type="Actual">September 15, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate as the percentage of participants with response.</measure>
    <time_frame>1year</time_frame>
    <description>Overall response rate is defined as the proportion of subjects who achieved complete response CR or partial response PR. Response criteria are based on NIH cGVHD Response assessment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>1year</time_frame>
    <description>DOR is defined as the duration of time from the date of initial response</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Chronic Graft-versus-host-disease</condition>
  <arm_group>
    <arm_group_label>therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>therapy with 1 arm. Anlotinib 8mg qd po。</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anlotinib</intervention_name>
    <description>anlotinib 8mg qd po</description>
    <arm_group_label>therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Participants must be diagnosed as hematopoiesis disorders and receiving hematopoietic&#xD;
             stem cells transplantation.&#xD;
&#xD;
          2. Steroid dependent or refractory classic chronic GVHD disease defined as modified&#xD;
             National Institutes of Health criteria(2014) below at any time post-hematopoietic cell&#xD;
             transplant(post-HCT)&#xD;
&#xD;
               1. Dependent disease, defined as, when glucocorticoid (prednisolone doses greater&#xD;
                  than or equal to(&lt;=) 0.25mg/kg/day or &lt;=0.5mg/kg every other day(prednisolone&#xD;
                  doses) due to recurrence or progression of cGVHD manifestations, it is considered&#xD;
                  as steroid-dependent disease if the lowest tapering dose of the second occasion&#xD;
                  is equal or higher than the lowest tapering dose of the first occasion&#xD;
&#xD;
               2. Refractory disease, defined as, when cGVHD manifestations progress despite the&#xD;
                  use of a regime containing glucocorticoid (prednisolone at &gt;=1mg/kg/day for at&#xD;
                  least 1 week) or persist without improvement despite continued treatment with&#xD;
                  glucocorticoid (prednisolone at &gt;=0.5mg/kg/day or 1mg/kg every other day) for at&#xD;
                  least 4 weeks.&#xD;
&#xD;
          3. Participants must be receiving baseline systemic glucocorticoid therpy for cGVHD at&#xD;
             study entry. The dose of steroids must be stable for 14 days prior to starting&#xD;
             anlotinib.&#xD;
&#xD;
          4. At the time of trial enrollment, participants may be receiving other immunosuppressive&#xD;
             therapies in addition to glucocorticoids. Immunosuppressant doses must be stable for&#xD;
             14 days prior to starting anlotinib.&#xD;
&#xD;
          5. Neutrophil≥1.5×109/L，platelet≥50×109/L&#xD;
&#xD;
          6. Karnofsky or Lansky performance status&gt;=60&#xD;
&#xD;
          7. Participants should sign the agreement.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known or suspected active acute GVHD.&#xD;
&#xD;
          2. Current treatment with a tyrosine kinase inhibitor, purin analogs or other cancer&#xD;
             chemotherapy in the 4weeks prior to starting study drug.&#xD;
&#xD;
          3. Concomitant use of warfarin or other Vitamin K antogonists.&#xD;
&#xD;
          4. Known bleeding disorders or hemophilia.&#xD;
&#xD;
          5. Known history of human immunodeficiency virus or active with hepatitis C. virus or&#xD;
             hepatitis B virus.&#xD;
&#xD;
          6. Uncontrolled infections not responsive to antibiotics, antiviral medicines, or&#xD;
             antifungal medicine or recent infection requiring systemic treatment .&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>xianmin song, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hematology Department</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200080</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>January 15, 2020</study_first_submitted>
  <study_first_submitted_qc>January 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2020</study_first_posted>
  <last_update_submitted>March 22, 2021</last_update_submitted>
  <last_update_submitted_qc>March 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Xianmin Song, MD</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

